

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No. ANG/21-22/BSE-40

Date 21-Feb-2022

To

Department of Corporate Affairs
BSE Limited'
P J Towers, Dalal Street
Mumbai – 400001

Ref: Script Code - 540694

Sub: Disclosure under Reg. 30 of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015.

Dear Sir/Madam,

Pursuant to Reg. 30 of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015. We hereby attach a copy of the Press Release titled "Q3 Earning Presentation of ANG Lifesciences India Limited" issued by the Company.

Kindly take the same on your record.

The said information is also being made available on the website of the Company at www.anglifesciences.com

Thanking You

Yours Faithfully,

For ANG Lifesciences India Limited


Renu Kaur
Company Secretary

PRESS RELEASE

Amritsar, February 14th, 2022: ANG Lifesciences India Limited (ANG), **one of the India's leading manufacturers of Finished Pharmaceutical Formulations**, Registered Office at Amritsar (PB), in its board meeting held on 14th FEB 2021 has inter-alia considered and approved the Unaudited Financial Results of the Company for the Quarterly and Nine months ended on 31st December 2021 as one of its agenda.

Financial Highlights (Consolidated) – Q3 FY22 Vs Q3 FY21

Particulars (INR Cr)	Q3FY22	Q3FY21	YoY(%)
Revenue	49.77	33.26	54%
EBITDA	5.48	1.74	215%
EBITDA Margin %	11 %	5 %	
PAT	1.27	0.22	3022%
PAT Margin %	2.56%	0.68%	

Financial Highlights (Consolidated) – 9M FY22 Vs 9M FY21

Particulars (INR Cr)	9MFY22	9MFY21	YoY(%)
Revenue	259.26	118.51	119%
EBITDA	54.98	11.19	391%
EBITDA Margin %	21%	9%	
PAT	35.07	5.66	520%
PAT Margin %	14%	5%	

9M FY22 Summary:-

- Total Income up at INR 259.26 Cr , registering a growth of 119% YoY.
- EBITDA of INR 54.98 Cr up 391 % YoY; EBITDA margin stood at 21%.
- Reported PAT of INR 35.07 Cr, registering a growth of 520% YoY ; PAT margin stood at 14%
- EPS at ₹ 33.93 Rs. Per share as compared to ₹ 9.90 Per share YoY; a Growth of 243%.

Management Comments

Commenting on the performance of Q3 FY21-22, Mr. Rajesh Gupta, Chairman & Managing Director, ANG Lifesciences India Limited said:

This Q3 result was embarked with great macro challenges, deceleration of economic activity and other issues related to logistics and supply of raw materials. During Q3 we have rescheduled / postponed our order books to Q4 due to increased Raw material price. Revenue growth was also impacted on account of plant closures for 15 days for plant maintenance and Shutdown activities. We have been striving continuously in pushing our Formulations business and thus have been spending extensively on acquisition's and promoting own brands through domestic branding. ANG's wide range of basket of 1000 formulations, and non-dependence on any one formulation helped us to clock a nine months turnover of INR 259 Cr. which is in F.Y. 2020-21 is only INR 154.93 Cr.

Going forward, we are confident to post strong performance, owing to healthy order book from domestic as well as Export and new launches, high demand and realization from existing key products and commencement of operations of our existing plant by end of FY22."

About ANG Lifesciences India Limited:


ANG Lifesciences India limited is a leading pharmaceutical company engaged in the business of manufacturing and marketing of finished pharmaceutical formulations in the form of tablets, capsules, liquid syrup, dry syrup (beta lactum & non-beta lactum) ointment, Lotion and Soft gelatin. Its key therapeutic areas are Injectable (dry & liquid) Antibiotic, Antiviral, Antimalarial, Antidiarrheal, Antiulcer, Anti-tuberculosis, Anti-Inflammatory, Carbapenem, Corticosteroid, Penicillin & Beta Lactamases Inhibitor & General pain management .The company has geographical presence across India, Africa, Latin America, Gulf Countries etc . Presently, **the company owns and operates 7 state of the art manufacturing facilities;** all in Baddi (H.P). These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities.

Forward-Looking Statement:

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward- looking statements. ANG Lifesciences India Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For more information, please contact

Renu Kaur Company Secretary Email: cs@anglifesciences.com



*YOUR TRUSTED
ASSOCIATE IN
HEALTHCARE*

**EARNING
PRESENTATION
9M FY22**



ANG LIFESCIENCES
INDIA LIMITED

SAFE HARBOR

Certain statements in this document may be forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. ANG Lifesciences India Ltd., will not be in anyway responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to Reflect subsequent events or circumstances



Consolidated Figures – Financial Highlights



Q3 FY-22

Revenue from operations **54%**

Rs. 49.77 Cr



EBITDA **215%**

Rs. 5.48 Cr

(EBITDA Margins: 11%)



Profit after tax **3022%**

Rs 1.27 Cr

(PAT Margins: 2.56%)




(Rs Cr)	Q3 FY-22	Q3 FY-21	YoY
Revenue from operations	49.77	32.26	54%
Cost of material consumed	32.42	19.75	
Employee expenses	5.58	4.41	
Other expenses	6.29	6.36	
EBITDA	5.48	1.74	215%
EBITDA margin	11%	5%	
Finance cost	2.00	0.93	
Depreciation	1.54	0.35	
PBT	1.94	0.46	320%
Tax Expenses	0.67	0.24	
PAT	1.27	0.22	3022%
PAT margin	2.56%	0.68%	
EPS	1.29	0.08	

Consolidated Figures – Financial Highlights



9 M F Y - 2 2


Revenue from operations **119%**
Rs. 259.26 Cr



EBITDA **391%**
Rs. 54.98 Cr
 (EBITDA Margins: 21%)



Profit after tax **520%**
Rs 35.07
 (PAT Margins: 14%)



(Rs Cr)	9M FY-22	9M F-Y21	YoY
Revenue from operations	259.26	118.51	119%
Cost of material consumed	160.83	80.83	
Employee expenses	15.53	10.68	
Other expenses	27.92	15.81	
EBITDA	54.98	11.19	391%
EBITDA margin	21%	9%	
Finance cost	4.99	2.52	
Depreciation	3.27	0.91	
PBT	46.72	7.76	502%
Tax Expenses	11.65	2.10	
PAT	35.07	5.66	520%
PAT margin	144%	5.0%	
EPS	33.93	9.90	
Paid up Equity	10.36	5.18	

Consolidated Figures – Financial Highlights



► Revenue Growth was impacted in Q3 mainly due to substantial increase in the costs of Raw Material and Packing Material could not be immediately passed on to the Customers and Long term Agreements with Government Institutions.


► Revenue Growth was also impacted on account of Plant shutdown for 15 days for Repair & Maintenance.

► Gradual improvement in Revenue Growth is Expected in the year end and Margin also should return back to Normalized level. Sales from Exports will grow in subsequent quarters.


Financial Highlights 9M




Operational Revenue (Cr)




EBITDA (Cr) & EBITDA Margins (%)




PAT (Cr) & PAT Margins (%)




Employee Expanse (Cr)




Finance Cost (Cr)




Depreciation (Cr)



Financial Snapshot Q3 FY22



Strategic Growth Path





Historical Financial



Financial Snapshot



Rs. (In Lacs)	2013	2014	2015	2016	2017	2018	2019	2020	2021
Income									
Income from Operations	1624.13	3449.93	3684.16	5492.3	6766.81	7604.47	12169.98	12683.11	15437.89
Other Income	3.73	9.46	9.46	21.03	25.02	68.72	23.27	41.97	55.58
Total Income	1628.64	3461.89	3693.63	5513.32	6791.82	7673.19	12193.25	12725.08	15493.48
Expenditure									
Cost of material consumed	1163.54	2594.26	2768.34	4107.11	4666.02	5321.12	8888.6	8955.67	10825.93
Change in Inventories	-32.02	-43.34	-87.18	-20.8	111.08	-31.74	-104.54	-58.76	-429.87
Employee Benefit Expenses	57.63	120.25	237	346.5	412.4	564.45	639.13	793.63	1367.56
Finance Cost	183.3	150.82	165.94	165.94	152.82	158.05	234.27	286.73	296.56
Depreciation & Amortization	67.14	305.12	94.64	105.98	117.04	119.15	112.37	122.87	131.68
Other Expenses	174.02	290.08	454.75	586.53	951.33	1046.83	1612.5	1784.31	2287.7
Total Expenses	1613.02	3417.19	3633.5	5291.26	6410.68	7177.88	11382.38	11884.47	14497.57
Profit Before Tax	15.02	44.7	60.13	222.06	381.14	495.31	810.86	840.62	1013.9
Total Tax Expense	21.23	25.4	19.73	56.58	89.14	122.91	245.97	231.06	311.14
Net Profit For the Year	-6.21	19.29	40.4	165.48	292	372.4	564.89	609.56	702.76

Business Strategy



To Increase Market Share ; Deeper Penetration Through Domestic Branding

Market Development ; Increase Geographical Footprints by Product Registration

Product Development ; By adding 50 Product formulations in current FY

Growth Strategy ; Through Meaningful Acquisitions

Product Registration ; 250 plus product Registration for Export in 2 year

ANG will strive for Operational Excellence by Manufacturing high Molecules

Create a Robust Growth for Consistent Profits

Professional Recruitment : to Strengthen Leadership

Focus on Export : Better & higher Realizations & Margins

Strengthening the Product Mix Thru Product Launch



THANK YOU

For more information, please contact:

Ms. RENU KAUR (Company Secretary)
ANG Lifesciences India Ltd.

SCO 113, 1st Floor, Darbara Complex, Ranjit Avenue, B-Block, Amritsar-143001, INDIA. Tel: 0183-5133463, 5133455
E-Mail: info@anglifesciences.com | cs@anglifesciences.com